Partner Therapeutics, Inc. (PTx), a private, fully integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) has awarded a Commissioner’s National Priority Voucher (CNPV) pilot program voucher for BIZENGRI® (zenocutuzumab-zbco) for the treatment of adults with advanced, unresectable or metastatic cholangiocarcinoma harboring a neuregulin 1 (NRG1) gene fusion with disease progression on or after prior systemic therapy.

Moderna, Inc. announced a publication in the New England Journal of Medicine of the positive Phase 3 study results evaluating mRNA-1010, its vaccine candidate for seasonal influenza. The peer-reviewed article summarizes the safety and efficacy data from Moderna's Phase 3 study (P304) evaluating the relative vaccine efficacy (rVE) of mRNA-1010 against influenza illness compared to a licensed standard-dose seasonal influenza vaccine in adults aged 50 years and older.

Cipla announced the launch of Ciposcillo®, an advanced oscillometer designed for accurate and precise assessment of respiratory mechanics. The device enables early diagnosis of obstructive airway diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Asthma. Built on US FDA cleared technology and engineered for Indian clinical practice, Ciposcillo® is CDSCO approved and ISO certified.

Metabolic and bariatric surgery offers significantly greater long-term protection against heart attack, stroke and death than widely-used GLP-1 drugs in older adults with obesity and diabetes, according to new real-world analysis study* presented today at the annual meeting of the American Society for Metabolic and Bariatric Surgery (#ASMBS2026).

Saveetha College of Pharmacy (SIMATS), Chennai, jointly in collaboration with the Indian Pharmaceutical Graduates' Association (IPGA) successfully organized a webinar titled “Pharmacy – World of Opportunities” on May 4, 2026. 

For more than 60 years. Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world's most discerning drug regulatory authorities like UK-MHRA. EDQM-Europe. and WHO Geneva, among others.